Monitoring response and resistance to EGFR inhibition with circulating tumor DNA in a non-small cell lung cancer patient-derived xenograft

被引：0
|
作者：
Do, Long H.
Pippa, Raffaella
Andrews, Warren
Chien, Yuan
Sperry, Jantzen
Nakashima, Jonathan
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-6690
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6690
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity
    Xuanming Chen
    Cheng Shen
    Zhe Wei
    Rui Zhang
    Yongsheng Wang
    Lili Jiang
    Ke Chen
    Shuang Qiu
    Yuanli Zhang
    Ting Zhang
    Bin Chen
    Yanjun Xu
    Qiyi Feng
    Jinxing Huang
    Zhihui Zhong
    Hongxia Li
    Guowei Che
    Kai Xiao
    CancerBiology&Medicine, 2021, 18 (01) : 184 - 201
  • [2] Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity
    Chen, Xuanming
    Shen, Cheng
    Wei, Zhe
    Zhang, Rui
    Wang, Yongsheng
    Jiang, Lili
    Chen, Ke
    Qiu, Shuang
    Zhang, Yuanli
    Zhang, Ting
    Chen, Bin
    Xu, Yanjun
    Feng, Qiyi
    Huang, Jinxing
    Zhong, Zhihui
    Li, Hongxia
    Che, Guowei
    Xiao, Kai
    CANCER BIOLOGY & MEDICINE, 2021, 18 (01) : 184 - +
  • [3] Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance
    Kita, Kenji
    Fukuda, Koji
    Takahashi, Hiro
    Tanimoto, Azusa
    Nishiyama, Akihiro
    Arai, Sachiko
    Takeuchi, Shinji
    Yamashita, Kaname
    Ohtsubo, Koshiro
    Otani, Sakiko
    Yanagimura, Naohiro
    Suzuki, Chiaki
    Ikeda, Hiroko
    Tamura, Masaya
    Matsumoto, Isao
    Yano, Seiji
    CANCER SCIENCE, 2019, 110 (10) : 3215 - 3224
  • [4] Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors
    R. B. Verheijen
    T. T. van Duijl
    M. M. van den Heuvel
    D. Vessies
    M. Muller
    J. H. Beijnen
    J. M. Janssen
    J. H. M. Schellens
    N. Steeghs
    D. van den Broek
    A. D. R. Huitema
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 269 - 276
  • [5] Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors
    Verheijen, R. B.
    van Duijl, T. T.
    van den Heuvel, M. M.
    Vessies, D.
    Muller, M.
    Beijnen, J. H.
    Janssen, J. M.
    Schellens, J. H. M.
    Steeghs, N.
    van den Broek, D.
    Huitema, A. D. R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (02) : 269 - 276
  • [6] The Use of Patient-Derived Xenograft (PDX) Models to Predict Patient Response in Non-Small Cell Lung Cancer (NSCLC)
    Isler, J.
    Katz, A.
    Sorogin, A.
    Scoppetuolo, M.
    Nechushtan, H.
    Pass, H.
    Davies, A.
    Paz, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S42 - S43
  • [7] Establishment of patient-derived tumor spheroids for non-small cell lung cancer
    Zhang, Zengli
    Wang, Huiqian
    Deng, Qifeng
    Xing, Yufei
    Xu, Zhonghua
    Lug, Chun
    Luo, Dongdong
    Xu, Longjiang
    Xia, Wei
    Zhou, Caicun
    Shi, Minhua
    PLOS ONE, 2018, 13 (03):
  • [8] Monitoring of circulating tumor DNA in non-small cell lung cancer patients treated with EGFR-inhibitors.
    Verheijen, Remy B.
    van Duijl, Tirsa T.
    van den Heuvel, Michel M.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    van den Broek, Daan
    Steeghs, Neeltje
    Huitema, Alwin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non-Small Cell Lung Cancer
    Amendt, Christiane
    Staub, Eike
    Friese-Hamim, Manja
    Stoerkel, Stephan
    Stroh, Christopher
    CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4478 - 4487
  • [10] Enhanced antitumor effect of dual EGFR and VEGFR2 inhibition in EGFR-mutated non-small cell lung cancer (NSCLC) patient-derived tumor xenograft (PDX) models
    Chintharlapalli, Sudhakar
    Fischl, Anthony
    Yu, Chun Ping
    Iversen, Philip
    CANCER RESEARCH, 2020, 80 (16)
12345